Exhibit 99.1
                                  ------------




DAUPHIN TECHNOLOGY, INC. ANNOUNCES MERGER AGREEMENT AMENDMENT

FOR IMMEDIATE RELEASE

SCHAUMBURG,  IL, JULY 12, 2006 -- Dauphin Technology,  Inc.  ("Dauphin"),  stock
symbol "DNTK.PK", and GeoVax, Inc., a privately held biotechnology company based
in Atlanta,  Georgia,  have signed an  amendment  to the  Agreement  and Plan of
Merger executed on January 20, 2006 ("Merger Agreement").  The amendment reduces
the amount of cash  Dauphin is required to have as a condition  of closing  from
$13,000,000 to $2,000,000. Dauphin has paid the required $2,000,000 to GeoVax to
fulfill this  condition.  Dauphin will use its best efforts to raise the balance
of $11 Million within 90 days after completion of the merger.

With  the  satisfaction  of the $2  Million  closing  requirement,  Dauphin  has
fulfilled  its material  closing  obligations  to date.  Within the coming days,
Dauphin will file an  Information  Statement  with the  Securities  and Exchange
Commission  (SEC).  Upon completion of the SEC's review and  satisfaction of any
remaining closing requirements, such as giving notice to Dauphin's shareholders,
Dauphin and GeoVax will be in a position to complete the merger.  The  amendment
also extends the time needed to satisfy these and other statutory requirements.

"We have  concentrated our efforts on satisfying  material  closing  conditions,
including  Dauphin  majority   shareholders'   approval,   financial   reporting
compliance  and bringing the Company's  reporting up to date. We are now down to
administrative and regulatory  tasks," said Andrew J. Kandalepas,  Dauphin's CEO
and Chairman.  GeoVax President & Chairman,  Don Hildebrand stated; "The advance
of  $2,000,000  prior to closing is a positive  step  towards  accelerating  the
closing of the transaction.  Our goal is to raise the balance of funds after the
closing  at  a  higher  valuation  to  maximize  existing   shareholder   value.
Additionally,  the $2,000,000  infusion of capital at this time allows GeoVax to
meet  commitments  related to its ongoing AIDS vaccine human clinical trials and
demonstrates  Dauphin's  ability  to raise  capital  for  GeoVax  and  Dauphin's
commitment to closing the transaction."

For More Information, Contact:
     Dauphin Technology
     847-303-6566

Certain matters  discussed in this news release are  forward-looking  statements
involving  certain  risks  and  uncertainties  including,  without  limitations,
changes in product demand, the availability of products,  change in competition,
economic conditions, various risks due to changes in market conditions and other
risks detailed in the Company's  Securities and Exchange  Commission filings and
reports.